Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute
| Autor: | Malcolm A. Smith, Larry Rubinstein, Edward L. Korn, Richard Simon, Richard S. Ungerleider |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Cancer Research
business.industry MEDLINE Commission medicine.disease United States Professional Staff Committees law.invention Clinical trial Patient safety National Institutes of Health (U.S.) Oncology Randomized controlled trial law Interim Humans Medicine Medical emergency Outcome data business Independent data Randomized Controlled Trials as Topic |
| Zdroj: | Journal of Clinical Oncology. 15:2736-2743 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.1997.15.7.2736 |
| Popis: | PURPOSE To describe the rationale for independent data monitoring committees (DMCs) for National Cancer Institute (NCI)-sponsored phase III cooperative group clinical trials. DESIGN We review the necessity for interim monitoring of outcome data during the course of randomized clinical trials and summarize the reasons for establishing DMCs with requisite expertise and with appropriate independence from study investigators. RESULTS The important components of the policy for cooperative group DMCs are described with a focus on the makeup of these bodies and on the complementary roles of study committee leadership and DMCs in protecting patient safety during the conduct of randomized clinical trials. CONCLUSION The cooperative group DMCs that are independent of the study committees and that have the requisite expertise to examine accumulating data and to base decisions on monitoring guidelines that are specified in advance by the study committee provide a body able to protect patient safety, to protect the integrity of the clinical experiments on which patients have consented to participate, and to assure the public that conflicts of interest do not compromise either patient safety or trial integrity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|